Gareth Tudor-Williams Imperial College London UK
description
Transcript of Gareth Tudor-Williams Imperial College London UK
![Page 1: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/1.jpg)
Young person with multi-class resistance: follow-up and management
(with perspectives from well-resourced and resource-limited settings)
Gareth Tudor-WilliamsImperial College London
UK
![Page 2: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/2.jpg)
Where would you prefer to be right now?
Langkawi resort?Attending a workshop?
![Page 3: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/3.jpg)
Young person with multi-class resistance: follow-up and management
(with perspectives from well-resourced and resource-limited settings)
Gareth Tudor-WilliamsImperial College London
UK
![Page 4: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/4.jpg)
Context• In many resource-rich settings, young
people with perinatally acquired HIV who are now in their mid-teens started on sub-optimal regimens in the pre-cART era.
• Typically dual therapy, such as AZT + 3TC, or d4T and ddI were used.
• Nelfinavir (unboosted) and ritonavir in therapeutic doses were our early PI’s.
• NNRTI’s were added to failing regimens.
![Page 5: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/5.jpg)
Thankfully, the lessons have been learned!
Less chance of selecting triple class resistance with today’s
combination therapy
![Page 6: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/6.jpg)
Case history
• 15 year old girl, Zambian parents• VL 96,000 c/ml off treatment / CD4=280• Previous treatment:
– AZT 3TC DDI TDF NFV RTV EFV• Can swallow tablets• Weighs 42 kg• No known allergies• Aware of her HIV status
![Page 7: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/7.jpg)
Would you do a resistance test now?
I would do a test: I would not do a test now:
![Page 8: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/8.jpg)
HIV resistance mutations• Adherence has been a long-standing problem and she
has never sustained an undetectable VL for any consistent length of time.
• She has had a number of resistance tests over the years• Right now, not much point in repeating resistance test
since she has been off treatment• Cumulative mutations from previous tests are more
helpful, plugged into Stanford data base:http://sierra2.stanford.edu/sierra/servlet/JSierra?action=mutationsInput
![Page 9: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/9.jpg)
![Page 10: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/10.jpg)
![Page 11: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/11.jpg)
![Page 12: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/12.jpg)
15yrs – triple class resistance
![Page 13: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/13.jpg)
In a well resourced setting:
• More information required to help decide what else to offer:
– Is she co-infected with HBV or HCV?
![Page 14: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/14.jpg)
If she is HBV infected, would you recycle lamivudine in next
regimen?I would prescribe
3TCI would not include
3TC
![Page 15: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/15.jpg)
In a well resourced setting:
• More information required to help decide what else to offer:
– Is she co-infected with HBV or HCV? NO
– HLA B*5701 status?
![Page 16: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/16.jpg)
Where you work, do you have access to HLA B*5701 testing?I do have access I do not have access
![Page 17: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/17.jpg)
In a well resourced setting:
• More information required to help decide what else to offer:
– Is she co-infected with HBV or HCV? NO
– HLA B*5701 status? Negative
– HIV tropism?
![Page 18: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/18.jpg)
Current co-receptor binding inhibitors work best against which
strain of HIV?CXCR4 CCR5
![Page 19: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/19.jpg)
Tropism = which co-receptor on the CD4+ lymphocyte is being used by the virus to bind to the cell
![Page 20: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/20.jpg)
stage Blocked by 1 Binding &
FusionCCR5 co-receptor inhibitor (Maraviroc)Fusion inhibitor (Enfuvirtide = T20)
2 Reverse transcript’n
NRTI’s (3TC, ABC)NNRTI’s (NVP, EFV)
3 Integration Integrase inhibitors(Raltegravir)
4 Transcription
5 Assembly Protease inhibitors(Lopinavir / ritonavir)
6 Budding and maturation
Maturation inhibitors
Targets for currently available inhibitors
![Page 21: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/21.jpg)
In a well resourced setting:
• More information required to help decide what else to offer:
– Is she co-infected with HBV or HCV? NO
– HLA B*5701 status? Negative
– HIV tropism? X4
![Page 22: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/22.jpg)
‘Virtual clinic’ recommendation, 2010
Virtual clinic = our HIV team, plus virologist / lab scientist, monthly meeting
• Darunavir 600mg twice daily• Ritonavir 100mg twice daily• Raltegravir 400mg twice daily• Truvada 1 tablet once daily
![Page 23: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/23.jpg)
Management
• Multi-disciplinary support for adherence• Seen every two weeks for first month, plus
phone calls from clinical nurse specialist• No significant adverse effects• Viral load tested 4 weeks after starting
new regimen – excellent response, which reinforces her ability to adhere
• Follow-up visits gradually extended to 3m.
![Page 24: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/24.jpg)
2012: VL<50 for 1 year - would like once daily regimen….
![Page 25: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/25.jpg)
Recent FDA approval• Darunavir once daily for ARV naïve without DRV
resistance mutations:• ARV-naive children 3 to under 12 :
– 10 to under 15 kg: 35/7 mg/kg once daily– 15 to under 30 kg: 600/100 mg once daily– 30 to under 40 kg: 675/100 mg once daily
• ARV-naive adolescents 12 to <18 yrs:– 40 kg or more: 800/100 mg once daily
http://www.natap.org/2013/Pharm/Pharm_13.htm
![Page 26: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/26.jpg)
(I54S, V82A)
DRV susceptible
![Page 27: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/27.jpg)
Virtual Clinic discussion 2012
?? OD DRV/r +Truvada + Third agent ? – potential low level R to rilpivirine (2nd generation NNRTI)? Wait elvitegravir / dolutegravir?? OD Raltegravir
Decided to go for once daily DRV 800 / RTV 100 plus Truvada, with close monitoring of viral load… so far, so good!
![Page 28: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/28.jpg)
Resource-limited setting
• 15 year old girl• VL 96,000 c/ml off treatment / CD4=280• Previous treatment:
– AZT 3TC DDI TDF NFV RTV EFV• Can swallow tablets• Weighs 42 kg• No known allergies• Aware of her HIV status
![Page 29: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/29.jpg)
Resource limited setting:
• More information required to help decide what else to offer:
– Is she co-infected with HBV? NO
– HLA B57*01 status? Know your population!
– HIV tropism? Not (currently) relevant
![Page 30: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/30.jpg)
Prevalence of HLA B*5701 varies according to ethnic background
![Page 31: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/31.jpg)
HLA B*5701 prevalence
Ethnicity n = % positive
White / Eurasian 654 8
Niger / Congo 573 0.5
Black Caribbean 82 0
South Asian 42 5
East Asian 12 0
![Page 32: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/32.jpg)
HLA B*5701 prevalence in African populations
![Page 33: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/33.jpg)
Would you treat her with 3TC monotherapy?
Yes, I would No, I wouldn’t
![Page 34: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/34.jpg)
HIV resistance
• Much can be inferred without access to resistance testing
• Need to know what regimens she has had, and how long she was on a failing regimen
• Failure on 3TC – expect M184V mutation• Failure on NNRTI – predictable resistance• Trials such as the PENPACT 1 study
provide some insights:
![Page 35: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/35.jpg)
PENPACT 1 (PENTA 9 / PACTG 390)
Antiretroviral therapy initiation with a PI versus an NNRTI combination and switch at higher
versus low viral load in HIV-infected children:
an open randomised controlled phase 2/3 trial
Lancet Infect Dis 2011; 11: 273-283
![Page 36: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/36.jpg)
A long-term comparison in ART naïve children of:
• PI-based versus NNRTI-based initial therapy
• two different viral load criteria for switching from 1st to 2nd line therapy:
>1,000 versus >30,000 copies/ml
PENPACT 1 trial (PENTA / IMPAACT)
![Page 37: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/37.jpg)
Time to Switch by Drug Class
At trial end PI (N=131) NNRTI (N=132)
On 1st regimen 96 73% 92 70%
0.00
0.25
0.50
0.75
1.00
Pro
porti
on o
f chi
ldre
n no
t sw
itche
d
0 24 48 72 96 120 144 168 192 216 240 264 288
Weeks from randomisation
p=0.64
PINNRTI
Only 4 (2%) children switched to 3rd line
![Page 38: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/38.jpg)
Time to Switch by Viral Load Switch-point
0.00
0.25
0.50
0.75
1.00
Pro
porti
on o
f chi
ldre
n no
t sw
itche
d
0 24 48 72 96 120 144 168 192 216 240 264 288
Weeks from randomisation
p=0.04
1,000
30,000
HIV-1 RNA at switchc/ml, median (IQR)
1,000 30,000 p-value
6,720 (1,380; 26,100)
35,712 (8,060; 72,800)
<0.01
![Page 39: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/39.jpg)
Resistance testing
Samples tested for resistance:Last sample with viral load >1000c/ml
• before switch• at confirmed viral load >1000c/ml before re-suppression
(to ensure a fair comparison between the 1000 and 30000 groups)• at 4 years• at trial end
![Page 40: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/40.jpg)
If she was ‘failing’ on NVP for a year, would she have accumulated more NVP resistance
than if she had switched as soon as VL reached 1,000 c/ml?
Yes, more resistance No, no greater resistance
![Page 41: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/41.jpg)
Cumulative Resistance at end of follow-up
1,000 30,000 P-value*
Total childrenNumber expected to have testsNumber with tests
1346051
1294840
PI resistance1 or 2 mutations 11 (9%) 5
(4%)
0.27
NNRTI resistance1 or 2 mutations3 or more mutations
18 (14%)3 (2%)
16 (13%)5 (4%)
0.50
High-level etravirine resistance
1 (1%)
2(2%)
**
Analysis assumes those without tests were not resistant. *Poisson regression ** score 5 on Stanford scale
![Page 42: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/42.jpg)
Cumulative Resistance at end of follow-up
PI 1,000
PI 30,000
NNRTI 1,000
NNRTI30,000
P value
Total childrenNumber expected to have testsNumber with tests
6633
28
6523
18
6827
23
6425
22
NRTI resistance1 or 2 mutations3 or more mutations
9 (15%)3 (5%)
6 (10%)3 (5%)
14 (22%) 0 (0%)
12 (20%)7 (11%)
0.001**
** Driven by more children with ≥ 3 NRTI mutations in NNRTI switch at 30,000 c/ml arm
![Page 43: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/43.jpg)
Start NNRTIs: 1000 group Potential NRTIs for second-line
n first-line ZDV ddI 3TC ABC 1 3TC ABC EFZ low - - - 2 3TC ABC EFZ - - high pot. low 3 3TC ABC EFZ - inter. high high
4 3TC d4T EFZ - - - -
5 ZDV 3TC EFZ - - - - 6 ZDV 3TC EFZ - - - - 7 ZDV 3TC EFZ - - - - 8 ZDV 3TC EFZ - - - - 9 ZDV 3TC EFZ - - high pot. low
10 ZDV ddI EFZ inter. low - low
11 3TC d4T NVP - low high low 12 3TC d4T NVP - - high pot. low 13 3TC d4T NVP - - high pot. low
14 ZDV 3TC NVP - - high pot. low 15 ZDV 3TC NVP - - - - 16 ZDV 3TC NVP - - high pot. Low 17 ZDV 3TC NVP low low high inter. 18 ZDV 3TC NVP - - high pot. low
19 ZDV ABC NVP inter. low - low
20 ZDV ddI NVP - - - -
Stanford score- = 1 fully
susceptiblepot . low = 2 potential low low = 3 low Inter. = 4 intermediate high = 5 high
Example
14 children start on 3TC ZDV/d4T + NNRTI
WHO 2010 recommends 2nd line:
ABC 3TC LPV/r : 5 fully susceptibleORABC ddI LPV/r : 5 fully susceptible
![Page 44: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/44.jpg)
Start NNRTIs: 30000 group
Potential NRTIs for second-line n first-line ZDV ddI 3TC ABC
1 3TC ABC EFZ - - high pot. low 2 3TC ABC EFZ - high high high
3 ZDV 3TC EFZ - - high pot. low 4 ZDV 3TC EFZ - - high pot. low 5 ZDV 3TC EFZ - pot. low high pot. low 6 ZDV 3TC EFZ - - high pot. low 7 ZDV 3TC EFZ inter. inter. high inter. 8 ZDV 3TC EFZ - pot. low high low 9 ZDV 3TC EFZ inter. pot. low high low 10 ZDV 3TC EFZ low high high high
11 ZDV ddI EFZ inter. inter. - low 12 ZDV ddI EFZ - - - - 13 ZDV ddI EFZ low - - - 14 ZDV ddI EFZ inter. low - low
15 3TC ABC NVP - - high pot. low 16 3TC d4T NVP - - high pot. low 17 3TC d4T NVP pot. low - - - 18 3TC d4T NVP - - high pot. low 19 3TC d4T NVP inter. pot. low high low 20 3TC d4T NVP high inter. high inter.
21 ZDV 3TC NVP - - high pot. low 22 ZDV 3TC NVP high high high high
Stanford score:- = 1 fully susceptiblepot . low = 2 potential low low = 3 low inter. = 4 intermediate high = 5 high
Example
15 children start on 3TC ZDV/d4T +NNRTI
WHO 2010 recommends second-line:
ABC 3TC LPV/r :1 fully susceptibleORABC ddI LPV/r :1 fully susceptible
![Page 45: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/45.jpg)
Start LPV/r: 30000 group Potential NRTIs for second-line n 1st line ZDV ddI 3TC ABC 1 3TC d4T LPV - - - - 2 ZDV 3TC LPV - - - - 3 ZDV 3TC LPV - - - - 4 ZDV 3TC LPV inter. low - pot. low 5 ZDV 3TC LPV - - - - 6 ZDV 3TC LPV - - high pot. low 7 ZDV 3TC LPV inter. inter. high inter.
Example
7 children started on 3TC ZDV/d4T + LPV/r
WHO recommends second-line:
ABC 3TC EFV : 4 fully susceptibleORABC ddI EFV : 4 fully susceptible
![Page 46: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/46.jpg)
Management
• Use boosted PI (i.e. Kaletra, if that’s what is available)
• Recycle available options• Push for access to newer agents –
darunavir / atazanavir / raltegravir and in due course dolutegravir….
• GOOD LUCK!
![Page 47: Gareth Tudor-Williams Imperial College London UK](https://reader036.fdocuments.net/reader036/viewer/2022081503/568164e5550346895dd74cba/html5/thumbnails/47.jpg)
With many thanks toDr Caroline Foster
and my colleagues in the HIV Family Clinic,Imperial College Healthcare NHS Trust,
London UKand colleagues in
Paediatric European Network for Treatment of AIDS (PENTA)
especially Linda Harrison for PP1 analyses